Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - AccuredRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fate Therapeutics (FATE) Current Leases (2019 - 2025)

Fate Therapeutics (FATE) has disclosed Current Leases for 7 consecutive years, with $4.6 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Current Leases fell 38.48% year-over-year to $4.6 million, compared with a TTM value of $4.6 million through Dec 2025, down 38.48%, and an annual FY2025 reading of $4.6 million, down 38.48% over the prior year.
  • Current Leases was $4.6 million for Q4 2025 at Fate Therapeutics, down from $4.8 million in the prior quarter.
  • Across five years, Current Leases topped out at $7.4 million in Q4 2024 and bottomed at $4.4 million in Q1 2021.
  • Average Current Leases over 5 years is $5.7 million, with a median of $5.7 million recorded in 2022.
  • The sharpest move saw Current Leases skyrocketed 132.46% in 2021, then tumbled 38.48% in 2025.
  • Year by year, Current Leases stood at $5.6 million in 2021, then rose by 0.91% to $5.6 million in 2022, then grew by 9.74% to $6.2 million in 2023, then increased by 20.08% to $7.4 million in 2024, then crashed by 38.48% to $4.6 million in 2025.
  • Business Quant data shows Current Leases for FATE at $4.6 million in Q4 2025, $4.8 million in Q3 2025, and $5.7 million in Q2 2025.